

# Subject Index

BR: Book review  
CR: Conference report

## A

- A<sub>1</sub> adenosine receptor
  - antagonists 240
- Academia, trends in awareness
  - of value of research 436
- Academic research,
  - commercialization 421
- ACAT inhibitors *see* Acyl-CoA
  - cholesterol acyltransferase (ACAT)
- Accelerated Intelligent Drug
  - Design (AIDD) system (CR) 199
- Acetogenins, bioactive 351
- Acetylcholine, enhancers of
  - action 219
- Acetylcholine receptors
  - muscarinic *see* Muscarinic
  - acetylcholine receptors
  - nicotinic *see* Nicotinic
  - acetylcholine receptors
- Actinoplanic acid B 32
- Acyl-CoA cholesterol
  - acyltransferase (ACAT)
  - enzymology 19, 20
  - expression and regulation 20
  - inhibitors 19–25
    - adrenal toxicity 23
    - adrenotoxic agents 24
    - bioavailable 21
    - early clinical studies 21, 22
    - non-adrenotoxic agents 25
    - strategies to avoid adrenal toxicity 24
  - isoforms 20
- Adenosine deaminase, inhibitor,
  - combinatorial library 192
- Adhesion molecules
  - drug target in asthma (CR) 396
  - inhibitors, in airway
    - inflammation management (CR) 533
  - see also* ICAM-3
- Adrenal toxicity, ACAT inhibitors
  - 23, 24
- Adrenergic agents, combinatorial
  - library 388
- $\alpha_1$ -Adrenoceptor antagonists 240
- $\alpha_{1A}$ -antagonists, uroselective 44
- $\alpha_{1B}$ -antagonists, potent 350, 351
- $\alpha_2$ -Adrenoceptors, for LNP509 (CR) 445
- $\beta$ -Adrenoceptors
  - in adipose tissue 254, 255
  - agonists 388
  - $\beta_3$ -agonists 255
  - as weight control drug target 426
- Affinity NMR, combinatorial
  - screening 242
- Affymetrix 14
- Africa, biodiversity inventory 401
- AGENE Research Institute 394
- Aging, research, in Japan 394
- Agmatine (CR) 446
- Agouti signaling protein (ASP) 254
- Agriculture, animal, animal
  - embryo as drug target 367–369
- Airway inflammation (CR) 431
  - drug management (CR) 532–535
- Akagerine 235
- Alcuronium 215
- Alendronate 69–77
  - bone quality affected by 75, 76
  - effect on bone mineral density 74, 75
  - effect on bone turnover 74
  - fracture incidence 76
  - safety 77, 78
  - structure 70
- Alosetron, in irritable bowel
  - disease 402
- Alprazolam 472
- Alzheimer's disease, marijuana 144
- American Chemical Society (ACS), on Ritalin 248
- Amersham Pharmacia Biotech (APBiotec)
  - acquisition of Molecular Dynamics 439
  - agreement with Imaging Research Inc. 438
  - imaging technology for HTS 438, 439
- Amines, linkers for and release 556
- Aminopeptidase N inhibitors,
  - nonpeptide 240
- Anandamide 144
- Androgen receptor, nonsteroidal
  - agonist 239, 240
- Angiostatin, media hype and
  - impact 433, 434
- ANGIS (Australian National
  - Genomic Information Service) 527
- Animal agriculture, animal
  - embryo as drug target 367–369
- Animal cells, SAGE analysis 158
- Animal models, functional
  - evaluation of genes 186, 187
- Annona squamosa* 351
- 2nd Annual International
  - Conference on Cell Signaling: Signal Transduction and Gene Transcription 443–445
- 3rd Annual Conference of the
  - Society for Biomolecular Screening 7–9
- Anthraquinone 235, 236
- Anti-angiogenic activity,
  - anticancer drugs 147
- Antiatherosclerotic agents, ACAT
  - inhibitors 19–25
- Antibiotics
  - discovery, at level of gene 564–566
  - macrolides *see* Macrolides
  - for methicillin-resistant *Staphylococcus aureus* 480
  - new development targets 495–504
  - pilus biogenesis 498, 499
  - resistance 495
    - bacterial species 495
    - macrolide 259
- Antibodies
  - humanized (CR) 439, 440
  - therapeutic *see* Therapeutic antibodies
- Antibody-based drug research,
  - company collaboration 332
- Anticancer drugs *see* Anti tumor
  - agents
- Anti-CD3, SMART (CR) 440
- Antidepressants, in idiopathic
  - parkinsonism 137
- Antidiabetic drugs, troglitazone
  - see* Troglitazone
- Antifolates
  - flexible 540
  - modelling new drugs 543, 544
- Antifungal agents, discovery (CR) 102
- Antigene oligonucleotides 45, 144 (corrector)
  - synthesis methods 45
- Antihypertensive agent, selenium
  - compounds 51
- Anti-IgE therapy, asthma (CR) 395, 396
- Anti-IL-12 mAb (CR) 441
- Anti-inflammatory effects,
  - cytokines (CR) 397
- Anti-leukointegrin, humanized, for
  - acute inflammatory disorders (CR) 440
- Antileukotrienes, for asthma (CR) 395
- Antimalarial drugs 538–546

- antifolates *see* Antifolates
- novel, modelling 546
- resistance 538, 539
- Anti-MRSA agents 480
- Antinephritic agent, novel 239
- Antioxidant activity
  - benzoxathioles 81
  - glutathione 114
  - hypolipidemic agents 80
- Antisense constructs, interleukin 6 (IL-6) 211
- Antistatin 224, 225
- Anti-TGF $\beta$  mAbs, for fibrosis prevention (CR) 441, 442
- Antithrombotic agents
  - factor Xa inhibitors 223
  - see also* Factor Xa inhibitors
- Antitumor agents
  - design based on
    - farnesyltransferase inhibition 26–33
    - discodermolide 300
    - market size 349
    - natural agent 351
    - oral 189
    - quinone-based compounds 522
  - see also* Chemotherapy
- Antitumor effects, of IL-6 207, 208
- Antiviral therapy, influenza virus *see* Influenza virus
- Anxiety 471, 472
  - chronicity 477, 478
  - classification of disorders 476
  - comorbidity of disorders 477
  - generalized, disorder (GAD) 472, 477
  - treatment *see* Anxiolytic therapy
- Anxiolytic therapy 471–479
  - benzodiazepines 471–474
  - alternatives to 474–476
  - high placebo response rate problem 476, 477
  - new drug development problems 476–478
  - types 472–476
- AP-1
  - effect of oxidants/antioxidants on 120
  - inhibitor 296, 425
- Apoptosis
  - caspase inhibitor effect 360
  - caspase role 359
  - control, glutathione role 119, 120
  - efficacy of chemotherapeutic agents, assay 4
  - Fas-mediated, caspase-8 initiating 525
- Aptamers 265
  - advantages 268, 269
  - affinity, improvements 269, 270
  - efficacy 270, 271
  - generation 266, 267
  - as research reagents 272, 273
- selection 265–268
- stability 271, 272
- target validation and identification 272
- therapeutic applications 269–272
- Aqueous separations, techniques 509, 510
- 2-Arachidonylglycerol 144
- Arachnova 529, 530
  - interview with founder 435–437
- Argatroban 107
- Arginine vasopressin, antagonists 481
- Ariflo (SB207499) (CR) 533
- Arimidex, discovery (CR) 102
- ARNIE (solution-phase organic synthesizer) 506
- Arylpiperazide derivatives, phenylpiperazines 189
- Arylsilyl linker 45
- Aspartic protease inhibitors, screening 110, 111
- Asparvenone 142
- Asthma
  - airway inflammation management (CR) 532–535
  - phosphodiesterase inhibitors (CR) 532, 533
- Asthma drugs (CR) 395–399
  - adhesion molecules as target (CR) 396
  - anti-IgE therapy (CR) 395, 396
  - clinical study design (CR) 395
  - cytokines (CR) 396–398
  - drug development delays (CR) 395
  - gene expression and proteomics approach (CR) 398, 399
  - MAP kinase inhibitors (CR) 398
  - novel glucocorticoids (CR) 398
- Atherogenesis, troglitazone treatment 87
- Atopic eczema, FDA approval for Zemaphyte 60
- Attention deficit hyperactivity disorder (ADHD) 248
- Aurora Bioscience 12
- Autoimmune diseases, interleukin 6 (IL-6) 205
- Automated systems 343–349
  - automated tools (listing) 345
  - combinatorial chemistry 344, 345
  - genomics 348
  - HTS *see* High-throughput screening (HTS)
  - library management *see* Compound library management
- The Automation Partnership, robotic system for cell culture (CR) 446
- Award for Distinguished Achievement in Cancer Research (CR) 199
- Azalides 258
- Azithromycin 258
- B**
- Bacteria
  - antibiotic resistance 495, 496
  - cell wall anchoring proteins 500, 501
  - genomics 564
  - Gram-positive: surface protein expression pathway 500, 501
  - phylogenetic tree 565
  - virulence 496
- BAF [boc-aspartyl(O-methyl)-fluoromethylketone] 359, 360
- Bafilomycin A1 387
- Basic fibroblast growth factor (bFGF) 333
- Batimastat, discovery (CR) 101, 102
- Bayer AG
  - collaboration with Genzyme Corp 67
  - crop protection agents collaboration 332
- Bead-based assays 318
- Beilstein registry 57
- Benign prostatic hyperplasia (BPH) 44
  - PhotoPoint therapy 47
- Benzimidazoles (CR) 49
- Benzodiazepines 471–474
  - abuse reliability 473, 474
  - alternatives 474–476
  - cognitive impairment by 473
  - motor impairment by 473
  - rage 473
- Benzoxathioles, antioxidant activity 81
- Benzyl bromide linkers (CR) 48
- Benzylxyisoquinoline 524
- Berlex Labs, factor Xa inhibitor 227
- Bestatin 240
- BG9719 240
- BIBP3226 (NPY  $\gamma_1$  receptor antagonist) 253
- Bicalutamide 239, 240
- Bile acids 409–418
  - biosynthesis 409, 410
  - chlorambucil conjugates 412, 413
  - in combinatorial chemistry 417, 418
  - dimeric and trimeric 416, 417
  - drug targeting to liver/intestine by 411–415
  - enterohepatic circulation 410
  - inhibition 415, 416
  - HMG-CoA reductase inhibitor conjugates 414, 415
  - HMG-CoA reductase inhibitor hybrids with 415

- metabolism 410, 411
- as nonpeptide scaffolds 417, 418
- peptide drug conjugates 413, 414
- reabsorption inhibition 415, 416
- sequestrants 416
- as shuttles for drugs 412–415
- structural properties 409, 410
- transport systems 410, 411
- Binding assays 315
- Binding constants, simultaneous measurement 388
- Bio '98*, therapeutic antibodies (CR) 439–442
- Biochips
  - applications 486
  - microfabrication (CR) 485, 486
  - re-use vs disposable 486
- Biodiversity 246, 247
  - bioprospecting or biopiracy? (CR) 399–402
  - chemodiversity 232–238
  - economic pressures (CR) 399, 400
  - international system (CR) 400, 401
  - inventories (CR) 401
  - limitation to antibiotic discovery 565, 566
  - marine environment 300, 301
  - 'mining' 490
  - natural extracts
    - assessment 489, 490
    - isolation 490
  - see also* Diversity of compounds; Molecular diversity
- Biogenic amines, control of body weight 254–256
- Bioinformatics
  - advantages/disadvantages of systems 526 (CR) 9
  - high-throughput (CR) 198, 199
  - integrated approach 525–527
  - integration with evolutionary biology 564
  - limitations and challenges (CR) 198
  - options 527
  - proteomics application (CR) 195
  - training and courses 426–428
  - Zeneca Pharmaceuticals (CR) 197
- BioMedNet 243
- Biomolecular screening 304 (CR) 7–9
  - see also* High-throughput screening (HTS)
- Biopharmaceuticals
  - investment status 391, 392
  - market size 391
- Biopsy material, human, in pre-clinical discovery (CR) 193
- Biosensors, voltage-gated ion channel drug discovery 331
- Bioseparation, combinatorial technology application 50
- BioSignal, acquisition by Packard BioScience Company 422
- Biotechnology companies
  - drugs/NCEs developed 492, 493
  - numbers and markets 392
  - partnerships 17, 18
  - see also* Biopharmaceuticals; Pharmaceutical companies
- BiP, target in phage display 374
- Bisbenzimidine isoxazoline derivatives 141
- Bisphosphonates
  - mode of action 71
  - osteoporosis treatment 73–78
  - pharmacokinetics 70
  - pharmacological properties 69, 70
  - safety and efficacy 71–73
  - structures 70
  - see also* Alendronate
- Bis-quinolinium cyclophanes 190
- BLAST search (CR) 198
- Blood pressure, reduction with selenium compounds 51
- BMS184467 and BMS184382 31
- BMS185878 and BMS186511 31
- BMS187257 ( $\beta_3$ -adrenoceptor agonist) 255
- BMS193269 30
- Boehringer Mannheim, factor Xa inhibitor 227
- Bone
  - metabolism, IL-6 role 203, 204
  - mineral density, alendronate effect 74, 75
  - quality and alendronate effect 75, 76
  - resorption
    - IL-6 role 208, 209
    - inhibitors 387
  - turnover, alendronate effect 74
- Botanical products, FDA approval for Zemaephyte 60
- Brain
  - damage, caspase inhibitors preventing 359, 360
  - development, model 13
- Brain-derived neurotrophic factor (BDNF) 138
- Breast carcinoma, antitumor effect of IL-6 207
- Brevetoxins (CR) 532
- Bristol-Myers Squibb
  - Award for Distinguished Achievement in Cancer Research (CR) 199
  - matrix metalloproteinase inhibitors 196
- British Biotech (CR) 101, 102
- Bromazepam 472
- Bullacin B 351
- Buspirone 475
- Buthionine sulfoximine (BSO) 113
- BZA2B and BZA5B 30
- C**
  - C3b, target in phage-display 373
  - C7/3'-phth 215
  - C1976, ACAT inhibitor 21, 22
  - CAAX motif 26
  - CAAX tetrapeptides 28, 29
  - Caco-2 cell, drug metabolism and toxicology studies (CR) 8
  - Caenorhabditis elegans*, gene function studies 187
  - Calcium channels 324
    - blockers 326
    - from conotoxin (CR) 531
  - Caliper Technologies Corp., miniaturized analytical instruments, agreement 342
  - Cancer
    - apoptosis of cells, efficacy of chemotherapeutic agents 4
    - directed drugs 47
    - full-length sequence information on genes 92
    - generic drug market 349
    - interleukin 6 (IL-6) in 207
    - media hype over drug discoveries 433, 434
    - photoactive therapy 47
    - product launches 260
    - research in Japan 394
    - risk with estrogen replacement therapy 200
    - 'vascular addresses' 147
    - see also* Anti tumor agents; Tumors
  - Cancer Genome Anatomy Project (CGAP) 361
  - Cannabinoid receptors 389
    - selective CB<sub>2</sub> antagonists 388, 389
  - Carbapenems, for MRSA 480
  - Carbergoline
    - actions, adverse effects and dosages 132–135
    - in idiopathic parkinsonism 135, 136
  - Carbohydrate synthesis, solid-phase 482, 483
  - $\beta$ -Carbolines 474
  - Carboxylic acids, linkers for 555
  - Cardiac cells, fetal 367
  - Cardiac myxoma, interleukin 6 (IL-6) 205
  - Carpipramine 475

- Case Histories in Drug Discovery and Design* (SMR symposium) 50, 101, 102
- Caspase-8, as emerging molecular target 525
- Caspase enzymes 359
- inhibitors, BAF 359, 360
- Castleman's disease, interleukin 6 (IL-6) 205
- Catechol-*O*-methyltransferase (COMT) inhibitors *see* COMT inhibitors
- Cathenamine 235
- Cathepsin D inhibitors
- combinatorial design 280
- combinatorial library (CR) 150
- CCD camera systems, for ultra-HTS 438
- CCR1 antagonists 518
- CD8<sup>+</sup> cells, receptor binding HIV for immune evasion 298
- CD45 phosphatase, compounds inhibiting 462–464
- cDNA
- candidate genes 185
- human sequences 90–92
- SAGE procedure 155
- sequencing of full-length inserts 91
- wet-chip devices 405
- Cell adhesion molecules *see* Adhesion molecules
- Cell-based assays 316
- biomolecular screening (CR) 7, 8
- luciferase assays, HTS 65
- reporter assays, in miniaturized HTS 320, 321
- Cell culture, robotic system (CR) 446
- Cell-cycle inhibitors 142
- Cell lines, tumor, glabracins A and B active against 481
- Cell signaling (CR) 443–445
- Cell surface receptors, phage-displayed peptide libraries 373
- Central nervous system (CNS)
- inflammation, IL-6 in 205
- Cephalosporin derivatives, for MRSA 480
- CGP59326 (CR) 533
- Chaetomelic acid A 32
- Chaperone-usher assembly pathway 497–499
- ChemDiverse, 3D
- pharmacophore method 513, 514
- Chemical Abstracts Service (CAS) 57
- Chemical Design, acquisition by Oxford Molecular 332
- Chemical diversity, for lead generation libraries 513, 514
- Chemical genetics (CR) 150
- Chemical intelligence, in Informix database 548, 549
- Chemical libraries
- diversity 513, 514
- high-speed parallel synthesis 512
- Chemiluminescence nitrogen detector (CLIND) 483
- Chemodeoxycholic acid 409, 410, 417
- Chemodiversity of nature 232–238
- Chemokines 398, 534
- drug targets 518
- in inflammation 517, 518
- inhibitors (CR) 534
- natural inhibitors 518
- Chemotaxis, drug targets 518
- Chemotaxonomy, plant species 236
- Chemotherapy
- customized 4
- malignant cell response and glutathione role 113–121
- see also* Antitumor agents
- ChemWeb 243, 244
- Chenodeoxycholic acid 411
- Chin 3/6 215
- Chinese medicinal herbs 351
- Chip-based screening technologies 311, 312
- Chip technology 14, 15
- companies involved 14, 15
- see also* Biochips; DNA chips
- Chiral drugs, pharmacokinetics 248
- Chiroscience, matrix metalloproteinase inhibitors 196
- Chlorambucil, bile acid conjugates 412, 413
- Cholecystokinin
- antagonists 280
- receptors, anxiolytic drugs acting at 475, 476
- Cholesterol
- biosynthesis control 389
- esterification 19
- Cholesterol-lowering drugs, development 389, 390
- Cholic acid 409–411
- Chromatography
- MALDI-TOF-MS with (CR) 194
- molecular diversity
- assessment in natural extracts 489, 490
- $\alpha$ -Chymotrypsin 143
- Ciglitazone 50
- Ciguatoxins (CR) 532
- Cinchona* quinoline alkaloids 234
- Cirrhosis, interleukin 6 (IL-6) 206
- Cisplatin, glutathione conjugates 117
- Cistron Biotechnology, influenza A microencapsulation (CR) 49
- CI1011 (ACAT inhibitor) 24, 25
- CL277082 (ACAT inhibitor) 21
- CL316243 ( $\beta_3$ -adrenoceptor agonist) 255
- CLAIMS database 58, 59
- Clarithromycin 258
- Clinical diagnostics
- miniaturization 405
- pharmaceutical HTS vs 315, 316
- pharmaceutical technology merging 408
- proteomics applications (CR) 194
- Clinical study design, asthma drugs (CR) 395
- Clondronate, structure 70
- Clonidine, history (CR) 445
- Clorazepate 472
- Clozapine, in idiopathic parkinsonism 137
- CNS inflammation, interleukin 6 (IL-6) in 205
- Coagulation 223, 224
- Colony-stimulating factors (CSFs), therapeutic uses 122, 123
- Colorectal cancer
- fats triggering 535
- Combinatorial chemistry
- adenosine deaminase inhibitor library 192
- automated synthesis 344, 345
- automation 344, 345
- bile acids 417, 418
- cathepsin D inhibitors 280
- consortia for cost-effective drug discovery 1, 2
- DNA-binding compound library 143
- enzyme-labile linker 425, 426
- evolutionary 379–385
- explosion of compounds 108
- factor Xa inhibitors 223–231, 297
- gene expression inhibitor 425
- high-speed parallel synthesis (HSPS) 511–515
- human papillomavirus E2 binders 143, 144
- hydroxamate synthesis on solid phase 352
- at IKCOC-7 (CR) 149, 150
- InfoTech Pharma '98* (CR) 199
- kinase inhibitor libraries 524
- $\beta$ -lactam library 192
- library-derived PPAR ligands 352
- matrix metalloproteinase inhibitors 482
- matrix metalloproteinases 94
- molecularly imprinted polymers 297
- nonpeptide scaffolds 417, 418
- novel PPAR- $\gamma$  ligands 45
- oligocarbamate libraries 563

- oligosaccharide libraries 525
- protein tyrosine phosphatase substrates 143
- purine kinase inhibitor library 94
- radio-frequency-encoded taxoid library 45
- RNA binders 563
- screening mixtures using affinity NMR 242
- sensor arrays 524
- SH3-domain ligands 296
- simultaneous measurement of binding constants 388
- solid-phase carbohydrate synthesis 482, 483
- solution-phase 505, 506
  - equipment 506, 507
- structure-based design
  - integration 105–112
- substrate-based protein tyrosine kinase inhibitors 482
- sugar library templates 425
- tamoxifen analogues 94
- tetramic acid libraries 563
- thrombin inhibitor library 352
- thrombin inhibitors with nonbasic P1 side-chains 388
- traceless library approach 45
- virtual screening *see* Virtual screening
- wet chip design 408
- see also* Combinatorial libraries
- Combinatorial Chemistry
  - Optimization Assistant (CR) 199
- Combinatorial libraries 105
  - adenosine deaminase inhibitor 192
  - adrenergic agents 388
  - analysis by mass spectrometry 191, 192
  - automated management 345–348
    - see also* Compound library management
  - cathepsin D inhibitors (CR) 150
  - DNA-binding compounds 143
  - electrospray mass spectrometry analysis 191, 192
  - encoded 345, 381
  - factor Xa inhibitors 227, 297
    - screening 228–230
  - genetic algorithms 380
  - ion channel modulators 330, 331
  - ketoproline (CR) 48
  - kinase inhibitor 524
  - $\beta$ -lactams 192
  - large 379, 380
  - linkers *see* Linker groups
  - matrix metalloproteinase 94
  - microdroplet 242
  - new hardware (CR) 49
  - oligocarbamate 563
  - oligosaccharide 525
  - phage display *see* Phage display
  - PPAR inhibitors 352
  - protein tyrosine phosphatase substrates 143
  - purification methods/concerns (CR) 49
  - purine kinase inhibitor 94
  - selection of candidates 109
  - simplified characterization 483, 484
  - sugar templates 425
  - targeted synthesis of compounds 105–112
  - tetramic acid 563
  - thrombin inhibitors 352
  - virtual 107, 108
    - receptor-based screening 109
    - see also* Virtual screening
  - see also* Combinatorial chemistry
- Combinatorial technology
  - application to bioseparation 50
  - 'Nuts and Bolts' Forum (CR) 48, 49
- Compound diversity *see* Diversity of compounds; Molecular diversity
- Compound library management, automated 345–348
- automation advantages 348
- modular systems 347, 348
- see also* Combinatorial libraries
- COMT inhibitors 131–133
- Cone snails, drugs from (CR) 531
- Conference/congress
  - 2nd Annual International Conference on Cell Signaling: Signal Transduction and Gene Transcription 443–445
  - 3rd Annual Conference of the Society for Biomolecular Screening 7–9
  - 3rd IBC Interactive 'Nuts and Bolts' Forum on Combinatorial Technologies 48, 49
  - 7th International Kyoto Conference on New Aspects of Organic Chemistry (IKCOC-7) 149, 150
  - Bio '98 conference, therapeutic antibodies 439–442
  - Case Histories in Drug Discovery and Design (SMR symposium) 50, 101, 102
  - Conquering Airway Inflammation in the 21st Century 532–535
  - drugs from venoms 531, 532
  - Identification, Characterisation and Controversies on the Role of Imidazol Receptors 445, 446
  - InfoTech Pharma '98 197–199
  - Lead Identification to Candidate Selection – Discovery Strategies for Managing the Commitment to Development 6, 7
  - Medicines from Nature: Scientific, Legal and Ethical Aspects 401
  - Microtechnologies and Miniaturisation: Tools, Techniques and Novel Applications for the Pharmaceutical Industry (IBC conference) 148, 149
  - Molecular Arrays: Microfabrication for Biochips 485, 486
  - New Drugs for Asthma 395–399
  - Real Case Studies on Developing Effective Assays (IBC meeting) 97–99
  - Technical Advances & Applications of Proteomics in Drug Discovery, Clinical Development Safety Testing & Diagnosis 193–195
- CONJURE program 167
- Conotoxin (CR) 531
- Conquering Airway Inflammation in the 21st Century 532–535
- Consortia
  - cost-effective drug discovery 1, 2
  - genomics in Japan 393
- Contract research organizations (CROs) 435, 436
- Convention on Biological Diversity (CBD) (CR) 399–401
- Core system model 61–68
  - description 63, 64
  - theoretical comparative analysis 64–67
- Corixa corporation, acquisition of GenQuest 434
- Coronary artery disease (CAD) 19
- Cor Therapeutics, factor Xa inhibitor 226
- Corticotrophin-releasing factor 1 (CRF-1), receptor antagonists 562
- Corvas International, factor Xa inhibitor 227
- Costa Rica, biodiversity inventory and bioprospecting 401
- Cost-benefits
  - consortia for effective drug discovery 1, 2

- HTS systems 67  
miniaturization of HTS 299, 307, 314
- Costs  
efficiency effect and drug development costs 391, 392  
high-throughput screening (HTS) 310, 311  
predictions in drug development 487
- COX-2 inhibitors, novel 386
- CP113818, ACAT inhibitor 21, 23
- Creativity  
demands for and productivity relationship 420  
small companies/teams 353, 354
- Crop protection agents, company collaboration 332
- c-src*, structure (CR) 534
- CY9701, cell adhesion molecule inhibitor (CR) 533
- Cyanogenic glycosides 234, 235
- Cyanoguanidines, as anti tumor agents 189
- Cyclic MMP inhibitors 423
- Cyclic urea protease, inhibitors 561
- Cyclization-cleavage reactions 558, 559
- Cycloguanil 538
- Cycloreversion 558, 559
- CYP2D6 inhibition studies 466–470  
approaches 468, 469  
Supersomes™ system 466–470
- Cystic fibrosis transmembrane conductance regulator (CFTR), phenomics 12
- Cytochrome inhibition, high-throughput approaches 466–468
- Cytochrome P450  
inhibition studies 466–470  
*see also* CYP2D6 inhibition studies
- Cytokines  
anti-inflammatory effects (CR) 397  
in asthma (CR) 396–398  
chemotactic (CR) 398  
inhibition, airway inflammation management (CR) 533, 534  
receptors 123  
interactions with STATs 126, 127  
regulation, therapeutic application 122, 123  
signaling  
drug targets 520  
tyrosine phosphorylation 127, 128  
via JAKs and STATs 123, 124  
synthesis inhibitors (CR) 534  
*see also* Chemokines; *specific cytokines*
- Cytosolic proteins, target in phage-display 373, 374
- Cytotoxic drugs, glutathione role in resistance to 115–119
- D**
- D2E7 (human anti-TNF mAb) (CR) 441
- D2163 (matrix metalloproteinase inhibitor) 196
- Daiichi Pharmaceutical, factor Xa inhibitor 226
- Dapsone, in lupus nephritis 239
- Databases  
advantages/disadvantages of systems 526  
ESTs (CR) 198  
fragmentation codes 59  
influenza virus, on Web 442  
on Internet 243, 244  
management systems 548  
metabolism (CR) 198  
mining, human genome 180  
object-relational *see* Object-relational databases  
rapid application development (RAD) 549  
searching for nonstructural information 59  
structure-searchable 57  
topological search systems 59
- Datablade Development Kit 548
- Data handling, oligonucleotide synthesis 39–41
- Data management, object-relational databases *see* Object-relational databases
- Datamonitor  
cancer market 349  
product launches 260  
docetaxel, topotecan and gemcitabine markets 349  
market report on serotonin-2 dopamine-2 antagonists 200
- Daylight Chemical Information Systems, object-relational databases 547–551
- DDE linkers 555
- Decarboxylation, traceless 557
- DeCode Genetics 355–357
- Decussine 235
- Dehydroalanines 557
- Delayed ion extraction (DE), MALDI-TOF with 38
- DE MALDI-TOF, oligonucleotides 38
- Dendrotoxins (CR) 532
- Deoxycholic acid 411
- Depression, imidazoline receptors in (CR) 446
- Derwent Drug File 58
- Derwent World Patents Index 58
- Detoxification, of cytotoxic drugs, by glutathione 113–121
- DeveloGen, control genes in diabetes and obesity 99
- Developmental biology  
applications in animal agriculture 367–369  
for drug discovery 361–369  
model organisms for functional genomics 362, 363  
stem cells as therapeutic agents 365–367
- DHFR *see* Dihydrofolate reductase (DHFR)
- Diabetes mellitus 79  
drug discovery case histories 50, 51  
gene control, start-up company 99  
novel oral hypoglycemic agents 424  
rosiglitazone 50  
troglitazone treatment *see* Troglitazone
- DiaDexus 17
- Diagnostics *see* Clinical diagnostics
- Diagnostics companies, partnerships 17, 18
- Dialdehyde 23E
- Diaryl-sulphonamides 522
- Diazepam 472
- d*-Dicentrine 351
- Diethyl pyrocarbonate (DEP) 20
- Dihydrofolate reductase (DHFR) 538  
active site  
mutations 540–543  
structure 539, 540  
in antimalarial drug resistance 538, 539  
gene mutations 538–543  
for increased resistance 545  
inhibitors 533–546  
design of new drugs 543  
*Plasmodium falciparum* 538–543
- Diketopiperazines (DKPs)  
analogues 290–292  
matrix metalloproteinase inhibitors based on 482
- Dimerizers (CR) 150
- Dimethylformamidinium linker 555, 556
- Dimethyl W84 215
- Discodermolide 300
- Disease-controlling anti-rheumatic therapies (DCARTs) (CR) 441
- Dithiocarbamate carbapenems, for MRSA 480
- Diversa Corporation 246, 247
- Diversity analysis  
concepts 105, 106  
in lead generation libraries 515
- Diversity of compounds 305, 306, 381, 332  
measurement 381  
natural extracts, assessment 489, 490

- see also* Molecular diversity
- Diversity of nature *see* Biodiversity
- DNA
- adducts, 4-hydroxyequilenin 200
  - matching and mismatching 15
  - sequencing, *Island Hopping* technique patent 490
  - synthesis
    - high-throughput, instrumentation 37
    - solid-phase using phosphoramidite approach 35
- see also* Nucleic acid
- DNA-binding combinatorial library 143
- DNA chips 148
- DNA synthesizers, automated, oligonucleotide production 34–42
- DNAVEC project 393
- Docetaxel, market share 349
- Docking methods, virtual screening 172–176
- Dopamine
- agonists, artificial, in idiopathic parkinsonism 134–136
  - selective ligands 43, 44
- Dopamine D<sub>3</sub> ligands 44
- Dopamine D<sub>4</sub> receptor, antagonist 351
- Double minute 2 protein (DM2) 374
- Doxorubicin, peptides coupled to 147
- 3D Pharmaceuticals, factor Xa inhibitor 227
- Drug delivery, cancer 147
- Drug design
- case histories (CR) 101, 102
  - structure-based 106, 107
  - drugs from venoms (CR) 531, 532
- Drug development
- cost predictions 487
  - delays in asthma drugs (CR) 395
  - efficiency effect and costs per year 391, 392
  - EMA impact 488
  - secondary metabolites as leads 232–238
  - time scales 488
- Drug discovery
- case histories (CR) 101, 102
  - media hype and impact 433, 434
  - postgenomic 361, 362
  - see also specific subjects*
- Drug market, Middle East 95, 96
- Drug metabolism
- Caco-2 cell studies (CR) 8
  - drug discovery in 466–468
  - see also* Metabolism
- Drug resistance
- antimalarial drugs 538, 539
  - cytotoxic drugs, glutathione role 115–119
  - see also* Antibiotics
- Drugs, from venoms (CR) 531, 532
- Drug targeting, to liver and small intestine 411–415
- Drug targets
- adhesion molecules in asthma (CR) 396
  - animal embryo 367–369
  - antibiotics 495–504
  - embryonic proteins 363–365
  - Gram-negative bacteria 500
  - Gram-positive bacteria 501, 502
  - in inflammation and immunomodulation 516–521
  - influenza virus neuraminidase *see* Neuraminidase
  - nuclear proteins 365
  - obesity 250–256, 431 (correction)
  - toxins as probes (CR) 532
- 2D-similarity methods, in virtual screening 165
- Duo3 215
- DuoW 215
- DuPont, agreement over DuPont Merck Pharmaceutical Co. 332
- DuPont Merck Pharmaceutical Co.
- DuPont acquisition 332
  - factor Xa inhibitor 227
- DuPont Pharmaceuticals, DuPont Merck Pharmaceutical Co.
- trading as 332
- DX9065a 226
- Dysfunctional uterine bleeding, PhotoPoint therapy 47
- E**
- EB1053 (bisphosphonate), structure 70
- Eczema, atopic, FDA approval for Zemaphyte 60
- Elastase, leukocyte, inhibitors 44
- Electrochemical sensing system, for genes 9
- ‘Electronic noses’ 524
- Electrospray mass spectrometry, combinatorial library analysis 191, 192
- Embryonic cells, as therapeutic agents 365–367
- Embryonic proteins, as drugs or drug targets 363–365
- EMA (European Authority Evaluation of Medicines), impact on drug development 488
- Emerging molecular targets
- 2-arachidonylglycerol 144
  - in Alzheimer’s disease 144
  - caspase-8 525
  - HIV immune evasion 298
  - interleukin 13 298
  - lymphoid sulphotransferase 525
  - selective CB<sub>2</sub> cannabinoid antagonists 388, 389
  - for weight control 426
- Emphysema, macrophage metalloelastase 387
- EnCompass 527
- Endometriosis, interleukin 6 (IL-6) 205, 206
- Endostatin, media hype and impact 433, 434
- Endothelin, antagonists 191
- Entacapone
- actions, adverse effects and dosages 132, 133
  - in idiopathic parkinsonism 133
- Enterobacteriaceae*, pilus biogenesis 496–500
- Entrepreneurs, biopharmaceutical 392
- Entropy, virtual screening 175, 176
- Environments, extreme, bioactive molecules 246
- Enzymatic assays 315, 316
- HTS 65
  - miniaturized HTS 320
- Enzyme-labile linker 425, 426
- Enzymes
- novel from extreme environments 247
  - peptidic ligands 383
  - target in phage display 375
- Epilepsy, gene 185
- Erk2, X-ray crystallography (CR) 443, 444
- Erythromycin 257, 258
- Erythropoietin receptor, SHP-1 interaction inhibition 128, 129
- Escherichia coli*
- antibiotic resistance 495
  - pilus biogenesis pathway 496–500
- Escins 481
- Estrogen, interleukin 6 (IL-6) production inhibition 211
- Estrogen mimics, interleukin 6 (IL-6) production inhibition 211
- Estrogen receptor family, transcriptional regulation 521
- Ethnopharmacology-based approach 235
- 3β-(4-Ethyl-3-iodophenyl)nor tropane-2β-carboxylic acid methyl ester 142
- Etidronate, structure 70
- European Authority Evaluation of Medicines (EMA), impact on drug development 488
- Europium cryptate 334
- Evolutionary biology, bioinformatics integration 564
- Evolutionary chemistry 379, 382–384
- combinatorial 379–385

- Evolutionary methods, in virtual screening 165–168
- Evolutionary programming (EP) 383
- EVOscreen™ system 459
- Exelixis Pharmaceuticals, crop protection agents collaboration 332
- Exochelins, use after heart attacks 301
- Expressed sequence tags (ESTs) 90–92, 185  
databases (CR) 198
- Extreme environments, bioactive molecules 246
- Ex Vivo* Apoptotic (EVA) assay 4, 5
- Eye diseases, PhotoPoint therapy 47
- F**
- Factor Xa inhibitors 141, 190, 223–231, 562  
combinatorial chemistry 223–231, 297  
library screening 228–230  
library synthesis 227  
naturally occurring 224–226  
small-molecule 226, 227
- Farnesylation 26, 27
- Farnesylpyrophosphate 31
- Farnesyltransferase 27  
inhibitors 26, 27, 45, 190, 191  
design 26–33  
farnesylpyrophosphate analogs 31  
natural products 31  
peptidomimetics 28–31
- Fas-mediated apoptosis, caspase-8 initiating 525
- Fast optical biospecific interaction assay (FOBIA) 319
- Fats, colorectal cancer triggered by 535
- Ferrets, Ro640796 (neuraminidase inhibitor) studies 453, 454
- Fetal cells, cardiac 367
- Fibrosis, prevention by anti-TGFβ mAbs (CR) 441, 442
- Fingerprint assays 315
- Fluorescence  
cell-based, HTS for voltage-gated ion channel drugs 326–329  
HTRF *see* Homogeneous time-resolved fluorescence (HTRF)  
miniaturized HTS detection methods 319
- Fluorescence correlation spectroscopy 458, 459  
assays 459–462  
CD45 phosphatase assays 463, 464  
lead discovery and 457–465  
peptide cleavage-based protease assay 460, 461
- Src-SH2–phosphotyrosine-peptide binding 460
- 7-TM receptor binding assays 461, 462
- topoisomerase–DNA binding 459
- Fluorescence spectroscopy 458, 459
- Fluorescent-imaging plate-reader (FLIPR) system 328
- Fluorescent pH-sensitive probes 142
- Fluorescent resonance energy transfer (FRET) 309
- Food and Drug Administration (FDA), Zemaphyte approval 60
- Forearm fractures 77
- FR145237 (ACAT inhibitor) 21, 23
- FR165914 (β<sub>3</sub>-adrenoceptor agonist) 255, 431 (correction)
- Fractures 76, 77  
effect of alendronate on incidence 76
- Fragmentation codes 59
- Freidinger lactams, synthesis 559
- G**
- GABA<sub>A</sub> receptors 214
- Galanin, control of body weight 254
- Gallamine 215
- Gallium, effect on *Plasmodium falciparum* 103, 249 (correspondence)
- Gels, 2D, proteomics (CR) 193
- Gemcitabine, market share 349
- Gemfibrozil 80
- Gene(s)  
antibiotic discovery based on 564–566  
discovery, proteomics application (CR) 194  
disease, search 180–183  
electrochemical sensing system for 9  
functions, animal model studies 186, 187  
in human genome 179  
SAGE analysis 153  
identification methods 183  
'novel', sequencing 90, 91  
orthologous 566  
paralogous 566  
secondary, in phenomics 12  
sequence  
matching/mismatching technology 15, 16  
sequence and function correlation 12–14  
small molecules 380, 381
- Genecheck 16
- GeneChip® 297, 298  
collaboration over 297, 298
- Gene expression  
asthma drug development (CR) 398, 399
- high-throughput analysis using SAGE 152–159  
human genome 179, 180  
inhibitors 293, 425
- Gene expression chips 486
- GeneLogic 15
- Generalized anxiety disorder (GAD) 472, 477
- GENESEQ 58
- Gene therapy  
cancer 260  
idiopathic parkinsonism 138  
vector technology in Japan 393
- Genetic algorithms 380  
applications 380
- Gene transcription *see* Transcription
- Gene transfer, horizontal  
between species 566
- Gene triage process 183–186
- Genome  
human  
gene number 153  
SAGE analysis 153  
targets for drug discovery 361, 362  
*see also* Human Genome Project  
Icelandic people 355–357  
matching/mismatching technology 15, 16  
sequence, influenza virus 442
- GenomeNet 394
- Genome Therapeutics Corporation 18
- Genomics  
advances in technologies 11–18  
automated systems 348  
bacterial 564  
companies involved 11–18 (CR) 8  
expressed sequence tags (ESTs) 90–92  
functional 11–18  
model organisms 362, 363  
model systems 12  
gene chip collaboration 297, 298  
*InfoTech Pharma '98* (CR) 198, 199  
international workshop in Japan 394  
Japan 393, 394  
partnerships (company) 11, 12  
reasons for completing human cDNA sequences 90–92  
review 11–13  
switch from 'structure' to 'function' 92
- Genotyping  
applications and advances 12  
biochip applications 486  
methods 16
- Gen-Probe 15

- GenQuest, acquired by Corixa corporation 494
- Genzyme Corp., collaboration with Bayer 67
- Gepirone 475
- Geysers, microorganisms from 247
- GG167 (neuraminidase inhibitor) 450, 451
- Glabracins A and B 481
- Glass, microstructuring 148
- Glaucoma, applications of anti-TGF $\beta$  mAb (CR) 441, 442
- Glaxo Wellcome
- alosetron 402
  - new technology in lead optimization 505–510
- Glial-cell-line derived neurotrophic factor (GDNF) 138
- Glomerulonephritis, interleukin 6 (IL-6) 206, 207
- Glucocorticoids, novel, for asthma (CR) 398
- Glucose
- hepatic production 83
  - tolerance, impaired, troglitazone treatment 87
  - uptake inhibitors 481
  - utilization, troglitazone effect 83, 84
- Glutathione
- as antioxidant 114
  - biochemical reactions involving 114, 115
  - conjugates, formation 114, 115
  - control of apoptosis 119, 120
  - cytotoxic drug resistance mechanism 115–119
  - homeostasis, multidrug-resistance-related protein regulation 113–121
  - response of malignant cells to chemotherapy 113–121
  - transfection of cell lines 115
- Glutathione S-transferases 114, 115
- Glycogen phosphorylase, inhibitors 523, 524
- GR231118 (NPY Y<sub>1</sub> receptor antagonist) 253
- Graft rejection, kidney *see* Kidney transplant rejection
- Gram-negative bacteria
- novel drug targets 500
  - pilus biogenesis pathway *see* Pilus biogenesis pathway
- Gram-positive bacteria
- cell wall anchoring 500, 501
  - novel drug targets 501, 502
  - surface protein expression pathway 500, 501
- Growth/differentiation factors (GDF) 364
- Growth factors, as drugs/drug targets 363–365
- Growth hormone, secretagogue 480, 481
- H**
- H<sub>3</sub> receptor antagonist 295
- Haystack system 346, 347
- Haywain system 347
- Heart attacks, *M. tuberculosis* agents for use after 301
- Heart disease, chronic, interleukin 6 (IL-6) in 204
- Hedgehog* gene 364, 365
- Helicobacter pylori*, agent effective against 524
- Helix Research Institute (HRI) 393
- Hematopoiesis, IL-6 action 203
- Hematopoietic stem cells 367
- Hepatitis B virus, surface antigen, OST577 (human mAb) (CR) 440
- Hewlett-Packard Co., miniaturized analytical instruments, agreement 342
- Hexamethonium 215
- High-performance liquid chromatography (HPLC), CYP2D6 inhibition studies 468
- High-speed parallel synthesis (HSPS) 511–515
- High-throughput, oligonucleotide production 35–37
- High-throughput bioinformatics (CR) 198, 199
- High-throughput gene expression analysis, SAGE 152–159
- High-throughput screening (HTS) 160
- assays 65
  - defining HTS systems 63
  - effective, development (CR) 97–99
  - miniaturization (CR) 97
  - new technologies 308–310
  - novel techniques (CR) 97, 98
- automation 343, 344
- voltage-gated ion channel drugs 331
- batch vs concurrent assays 65, 66
- case studies (CR) 98
- chip technologies 311, 312
- clinical diagnostics vs pharmaceutical HTS 315, 316
- core system *see* Core system model
- cost issues 310, 311
- costs/benefits of systems 67
- drug discovery in drug metabolism 466–468
- future considerations 304–312
- impact on drug discovery and drug numbers 299
- implementation time 66
- InfoTech Pharma '98* (CR) 199
- inhibition of SHF-1 with erythropoietin receptor 128, 129
- laboratory management 92, 93
- miniaturization *see* Miniaturized HTS
- new imaging technology 438, 439
- new technologies, assessment 93
- patent strategies: 566
- productivity 67
- proximity assays (CR) 98, 99
- reliability 62, 63, 66, 67
- benefits 67, 68
  - of devices 61, 62
  - impact 61–68
- review 314, 315
- Scintillation Proximity Assay (SPA) 438
- smaller systems more productive than large systems 61–68
- small-molecule libraries, peptide application 376, 377
- traditional vs virtual screening 161, 162
- ultra-HTS levels 192
- virtual screening *see* Virtual screening
- voltage-gated ion channel drug discovery 323–332
- Hip fractures 77
- Hirsutine 189
- Hirulog, discovery (CR) 102
- HIV-1
- genotyping kits 60
  - immune evasion target 298
  - non-nucleoside reverse transcriptase inhibitor 387
- HIV infection, customised chemotherapy 4
- HIV protease inhibitors, discovery (CR) 101
- HMG-CoA reductase inhibitors 389, 414
- bile acid conjugates 414, 415
  - bile acid hybrids 415
- HMR3647 (macrolide) 258
- Hoffman-LaRoche
- deCode Genetics: agreement 356
  - factor Xa inhibitor 227
  - future predictions for R&D and interview 487–489
- Homogeneous time-resolved fluorescence (HTRF) assays
- optimizing reagent concentration: 335, 336
  - strategy 335
- principles 334, 335
- tyrosine kinase assays 333–342, 431 (correction)
- see also* Tyrosine kinases
- Homoserine lactones 557, 558
- Hormone receptors, ligands (CR) 443

- Hot springs, microorganisms from 247
- HTRF *see* Homogeneous time-resolved fluorescence (HTRF)
- HTS *see* High-throughput screening (HTS)
- Hu23F2G (LeukArrest™) (CR) 440
- Human biopsy material, in pre-clinical discovery (CR) 193
- Human Genome Project 179, 564  
analysis methods 179, 180  
disease genes, search 180–183  
gene number 179, 180  
Icelandic people participation 356  
for organic synthesis (CR) 150  
value/benefits of 179, 188  
*see also* Genome
- Human leukocyte elastase (HLE), inhibitors 44
- Human papillomavirus (HPV), E2 protein, binders 143, 144
- Human protein library 297, 298
- Hydroisindole derivatives, solid-phase synthesis (CR) 150
- Hydrothermal vent worms 247
- Hydroxamic acid, linkers (CR) 48
- 4-Hydroxyequilenin  
DNA adducts 200  
risk of cancer 200
- Hydroxyl radicals, in heart tissue after heart attacks 301
- 5-Hydroxytryptamine *see* Serotonin
- Hypercholesterolemia, bile acid sequestrants 416
- Hyperparathyroidism, primary, interleukin 6 (IL-6) action 209
- Hypertension  
imidazoline analogue  
treatment (CR) 445, 446  
troglitazone treatment 87
- Hypoglycemia, troglitazone actions 82
- Hypoglycemic agents, oral 424  
*see also* Troglitazone
- Hypolipidemic agents  
antioxidant activity 80  
*see also* Lipid lowering therapy
- Hyseq 14
- I**
- Ibandronate, structure 70
- 3rd IBC *Interactive 'Nuts and Bolts' Forum on Combinatorial Technologies* 48, 49
- ICAM-3, ICM3 humanized mAb recognising (CR) 440
- Icelandic people, genome 355–357
- ICM3 humanized mAb (CR) 440  
*Identification, Characterisation and Controversies on the Role of Imidazol Receptors* (CR) 445, 446
- IGEN International, new technique patent 521
- IκB kinase 517  
IKK-1 and IKK-2 444, 517
- Imaging, HTS 438, 439
- Imaging Research Inc., agreement with APBiotech 438
- Imidazol, receptors (CR) 445, 446
- Imidazoline analogues, hypertension treatment (CR) 445, 446
- Imidazoline receptor  
in depression (CR) 446  
endogenous ligand (CR) 446  
history (CR) 445  
signalling pathway (CR) 446
- Imidazol receptors, I<sub>1</sub>- and I<sub>2</sub>- (CR) 445
- Immune modulators, selective CB<sub>2</sub> cannabinoid antagonists 388, 389
- Immune response  
evasion by HIV 298  
IL-6 action 203
- Immunoglobulin E (IgE), anti-IgE therapy for asthma (CR) 395, 396
- Immunomodulation, new drug targets/compounds 516–521
- Immunosuppression, local, in idiopathic parkinsonism 139
- Immunosuppressive drugs  
novel 239  
Zenapax (humanized antibodies) (CR) 440
- Incadronate, structure 70
- Indexing, searching for nonstructural information 59
- Indolyldiketopiperazine alkaloids 559
- Infections, interleukin 6 (IL-6) in 204
- Inflammation  
chemokines action 517, 518  
drug targets 516–521  
interleukin 6 (IL-6) in 204  
TNF action 516
- Inflammatory bowel disease, interleukin 6 (IL-6) 205
- Inflammatory disorders, acute, humanized anti-leukointegrin for (CR) 440
- Inflammatory response, IL-6 role 203
- Influenza 448  
control 455  
epidemiology and surveillance 449  
pathogenesis and disease manifestation 450
- Influenza A  
antiviral agent 189  
microencapsulation into Novasomes (CR) 49
- Influenza virus 448, 449  
database on Web 442  
neuraminidase *see* Neuraminidase  
structure 451  
variability 451
- Information technology  
*InfoTech Pharma '98* (CR) 197–199  
Novartis (CR) 198  
Zeneca (CR) 197
- Informix database chemical intelligence 548, 549
- InfoTech Pharma '98*, knowledge management (CR) 197–199
- 'Innovation deficit,' pharmaceutical R&D 491–494
- Insulin, enhancement of action by troglitazone 84, 85
- Integrins  
nonpeptide antagonists 561, 562  
target in phage-display 373
- Intellectual property rights, biodiversity and (CR) 399, 400
- Interferons, therapeutic uses 122, 123
- Interleukin 1β (IL-1β), influenza A microencapsulation with (CR) 49
- Interleukin 2 (IL-2) Zenapax humanized mAb binding (CR) 440
- Interleukin 5 (IL-5)  
in asthma (CR) 397  
SCH55700 humanized antibody (CF) 534
- Interleukin 6 (IL-6)  
antisense constructs 211  
antitumor effects 207, 208  
biological activities 203, 204  
bone resorptor 208, 209  
in disease 204–209  
as drug discovery target 202–213  
knockout mice 204  
minibody polypeptide 210, 211  
neutralizing antibodies 210  
production inhibition by estrogen 211  
production regulation 202  
receptors 202  
antagonists 209, 210  
antibodies 210  
small-molecule inhibitors 211  
structure 202  
therapeutic approaches 209–211  
transgenic mice 204
- Interleukin 10 (IL-10), in asthma (CR) 397

- Interleukin 12 (IL-12)  
in asthma (CR) 397  
human mAb against (CR) 441
- Interleukin 13 (IL-13), as  
emerging molecular target 298
- 7th International Kyoto  
Conference on New  
Aspects of Organic  
Chemistry (IKCOC-7) 149, 150
- Internet  
bioinformatics training courses 427  
databases and literature 243, 244  
research community 244  
websites, patents/patenting 53  
*see also* World Wide Web
- Intracellular pH indicator 142
- Invention, small  
companies/teams 353, 354
- Ion channels, voltage-gated *see*  
Voltage-gated ion channels
- Ipsapirone 475
- I-receptor *see* Imidazoline  
receptor
- Irritable bowel disease, alosetron 402
- Island Hopping technique, patent 490
- Isoxazolidine-3,5-dione 424
- J**
- JAKs 122, 123, 124  
cytokine signaling via 123, 124  
drug targets 520  
structure and function 124, 125
- JAK-STAT pathway  
activation 124  
by IL-6 receptor 202, 203  
modulator discovery 122–130
- Janus kinases (JAKs) *see* JAKs
- Japan, genomics 393, 394
- JTT501 (hypoglycemic agent) 424
- K**
- Kaposi's sarcoma, interleukin 6 (IL-6) in 207
- Kazusa DNA Research Institute 393, 394
- Ketolides 259, 260  
compounds 258, 259  
potential 260  
resistance 259, 260
- Ketones,  $\alpha,\beta$  unsaturated, synthesis 554, 555
- Ketoproline libraries (CR) 48
- Kidney transplant rejection  
humanized antibodies for (CR) 440  
SMART anti-CD3 for (CR) 440
- Kinases  
inhibitor, libraries 524  
intracellular signalling 519, 520
- Knockdown studies 185, 186
- Knockout mice  
interleukin 6 (IL-6) 204  
STAT genes 125, 126
- Knowledge management,  
*InfoTech Pharma '98* (CR) 197–199
- Kribine 235
- L**
- L731734 (peptidomimetic) 28  
L731735 (peptidomimetic) 28  
L739749T (peptidomimetic) 28  
L739750 (peptidomimetic) 28  
L744832 (peptidomimetic) 28  
L755507 ( $\beta_3$ -adrenoceptor agonist) 255, 431 (correction)
- Laboratory management, HTS 92, 93
- $\beta$ -Lactamase, inhibitor 350
- $\beta$ -Lactams, combinatorial library 192
- Lactobacillus casei*, dihydrofolate reductase (DHFR) 540
- Lazabemide, in idiopathic parkinsonism 136
- Lead compounds, identification, management strategies (CR) 6, 7
- Lead discovery  
by miniaturized HTS 457–465  
new approaches 304–312
- Lead generation  
chemical diversity and 513, 514  
chemical libraries 512  
diversity analysis in libraries 515  
high-speed parallel synthesis 511–515
- Lead Identification to Candidate Selection – Discovery Strategies for Managing the Commitment to Development* (CR) 6, 7
- Lead optimization  
new technology 505–510  
small focused libraries for (CR) 8  
solution-phase chemistry *see* Solution-phase combinatorial chemistry  
take-up of new technology 508–510  
virtual libraries 275
- Leadseeker system 438
- Leptin 250, 251  
resistance during obesity 251, 252  
synthesis and nicotinic signalling 426
- Leukaemia, treatment, SMART M195 (CR) 440
- LeukArrest™ (CR) 440
- Leukemia, antitumor effect of IL-6 207, 208
- Leukocyte antigen receptor phosphatase, combinatorial library 143
- Leukocytes  
adhesion inhibition by humanized antibodies (CR) 440  
elastase (human) inhibitors 44
- Leukointegrins, humanized antibodies (CR) 440
- Libraries *see* Chemical libraries; Combinatorial libraries; Compound library management
- Ligands, use in chemical genetics (CR) 150
- Linker groups, novel (CR) 48, 49
- Linkers 552  
acid-labile 553–555  
DDE 555  
enzyme-labile 425, 426  
methacrylic 555  
nucleophile-labile 555, 556  
amine release 556  
oxycarbonyl resin 555  
photolabile 553  
Rink 553, 554  
silicon-containing 558  
for solid-phase synthesis 552–560  
*see also* Solid-phase synthesis  
sulphonyl and sulphon 556  
traceless 557, 558  
trityl 554  
Wang 553
- Lipid A analogues, solid-phase synthesis (CR) 150
- Lipid lowering therapy 19  
ACAT inhibitors 20, 21
- 5-Lipoxygenase, inhibitor 424
- Lithocholic acid 41
- Liver cirrhosis, interleukin 6 (IL-6) 206
- LNP509 (IL<sub>2</sub>-selective agonist) (CR) 445
- 'Lollipop' separations, aqueous phases 509
- Lorazepam 472
- Los Alamos National Laboratory (LANL), influenza virus database 442
- LPXTGX sequence, Gram-positive bacteria surface proteins 501
- Luciferase assays, HTS 65
- Luciferase reporter, miniaturized HTS 320, 321
- Lung cancer, early detection and treatment with PhotoPoint 47
- LY357897 (NPY Y<sub>1</sub> receptor antagonist) 253
- Lymphoid sulphotransferase, as emerging molecular target 525
- Lynx Pharmaceuticals 15

**M**

- Macrolides 257, 258
  - ketolides 257–260
  - resistance 259
  - see also* Ketolides
- Macrophage metalloelastase, inhibitor 387
- Malaria
  - drug discovery *see* Antimalarial drugs
  - gallium-based drugs 103, 249 (correspondence)
- MALDI-TOF, oligonucleotides 37, 38
- MALDI-TOF-MS, chromatography with (CR) 194
- Malindine 235
- Mammary carcinoma, antitumor effect of IL-6 207
- Management, strategies for selecting discovery candidates (CR) 6, 7
- MAO inhibitors
  - in idiopathic parkinsonism 136
  - MAO-A 136
  - MAO-B 136
- MAP kinase *see* Mitogen activated protein kinase (MAPK)
- Marijuana, in Alzheimer's disease 144
- Marine environment, biodiversity 300, 301
- Marine organisms, screening for active compounds 300
- Markush format, patented compounds 54
- MARPAT database 57
- Mass spectrometry
  - molecular diversity
    - assessment in natural extracts 489, 490
    - protein analysis/identification (CR) 194
- Mass spectroscopy, oligonucleotides 37, 38
- Matrix metalloproteinase (MMP)
  - discovery (CR) 101, 102
  - library 94
  - in tumor progression 196
- Matrix metalloproteinase (MMP) inhibitors 386, 387
  - clinical trials 196
  - collaborative deals 196
  - combinatorial chemistry 482
  - cyclic 423
- Media, hype over drug discovery 433, 434
- Medicines from Nature: Scientific, Legal and Ethical Aspects* (CR) 400
- MegaBACE 1000 DNA sequencing system (CR) 439
- Melanocortins, control of body weight 254
- $\alpha$ -Melanocyte stimulating hormone 254
- Melatonin receptors 190
- Mel<sub>1b</sub> ligand 190
- Melinamide 21
- Memory-enhancing drugs 144
- Mercaptoalcohols, diastomeric 386, 387
- Mercaptoketones, succinyl-based 386, 387
- Merrifield resin 555
- Mesenchymal stem cells 367
- Metabolism
  - databases (CR) 198
  - secondary 233, 234
  - see also* Drug metabolism
- Metabolites, secondary *see* Secondary metabolites
- Metabotropic glutamate receptor, antagonists 89
- Metalloelastase, macrophage, inhibitor 387
- Metformin, troglitazone with 87
- Methacrylic acid linkers 555
- Methoctramine 215
- O-Methylasparvenone 142
- N-Methyl-D-aspartate receptor (NMDA) antagonists 137, 138
- Methylenedioxyphenyl group 191
- Methyl ketones,  $\alpha,\beta$  unsaturated, synthesis 554, 555
- N-[<sup>3</sup>H]Methylscopolamine (NMS) 215, 217, 219
- MGLuR1 receptor antagonists 89
- Microdroplet, combinatorial library 242
- Microfluidics, CDs 485, 486
- Microorganisms
  - culture problems 246
  - diversity and chemicals from 246
  - phylogenetic tree 565
  - scale-up problems 246, 247
  - see also* Bacteria
- Microtechnologies and Miniaturisation: Tools, Techniques and Novel Applications for the Pharmaceutical Industry* (CR) 148, 149
- Microtiter plate
  - CYP2D6 inhibition studies 466–470
  - high-density format 148
- Middle East, pharmaceutical industry 95, 96
- Millennium Therapeutics 17
- Miniaturization (CR) 148, 149
- Miniaturization for drug discovery 404–408
  - wet-chip devices *see* Wet-chip devices
- Miniaturized analysis 148, 313–322
- Miniaturized analytical instruments, commercial agreement 342
- Miniaturized analytical thermocycler (CR) 149
- Miniaturized HTS 306–308, 313–322, 505
- 9600-well plate 318
- bead-based assays 318
- cell-based reporter assays 320, 321
- (CR) 9
- containers (1536-well plate) 317, 318
- cost-benefits 299, 307, 314
- detection methods 319, 320
- enzymatic assays 320
- fluidics 319
- fluorescence correlation spectroscopy 459–462
- lead discovery by 457–465
- need for 307, 308
- progress in primary screening assays 317–322
- reasons for 313, 314
- requirements 316, 317
- tyrosine kinase HTRF assay comparison 336, 339
- voltage-gated ion channel drugs 331
- voltage-gated ion channels 325
- Minibody polypeptide, interleukin 6 (IL-6) 210, 211
- Mirivant Medical Technologies 47
- Mitochondrial genome, on chip 14
- Mitogen-activated protein kinase (MAPK) 26, 27
  - cascades, drug target 520
  - I $\kappa$ B kinases (CR) 444
  - pharmacology (CR) 398
- Moclobemide, in idiopathic parkinsonism 136
- Modelling
  - antifolate antimalarials 543–546
  - novel antimalarials 546
- Molecular Arrays: Microfabrication for Biochips* (CR) 485, 486
- Molecular diversity
  - 3D pharmacophore method 513, 514
  - assessment in natural extracts 489, 490
  - see also* Diversity of compounds
- Molecular Dynamics, acquisition by APBiotec 439
- Molecular imprinting, polymers 297
- Molecular scaffolds, drugs from venoms (CR) 531, 532
- Monoamine inhibitors *see* MAO inhibitors
- Monoclonal antibodies (CR) 441
  - anti-CD3 (CR) 440
  - anti-ICAM3 (CR) 440
  - anti-IL-12 mAb (CR) 441
  - anti-leukointegrin (CR) 440
  - anti-TGF- $\beta$  mAbs (CR) 441, 442
  - anti-TNF- $\alpha$  (CR) 441
  - evolution and humanized antibody development (CR) 439

- human (CR) 439, 440
- anti-TGF $\beta$  (CR) 441, 442
- for rheumatoid arthritis (CR) 441
- humanized (CR) 439, 440
- anti-leukointegrin (CR) 440
- murine (CR) 439, 440
- Monosaccharides, library synthesis 425
- Monsanto Co., antibody-based drug research collaboration 332
- Moxonidine, receptors (CR) 445, 446
- MRSA (methicillin-resistant *Staphylococcus aureus*) 480
- Multidrug-resistance, phenotype 118
- Multidrug-resistance-related protein, regulation, glutathione role 113–121
- Multiple myeloma, interleukin 6 (IL-6) 207
- Multiple sclerosis, LeukArrest application (CR) 440
- Muscarinic acetylcholine receptors 214–222
- allosteric modulators 214–222
- development strategies 219–221
- ligand specificity 217, 218
- receptor specificity 217
- recognition sites 218
- therapeutic perspectives 218, 219
- types 215, 218
- MutS* genotyping method 16
- Mycobacterium tuberculosis*, compounds produced by 301
- Myriad Genetics, *Island Hopping* patent 490
- N**
- Nanolitre dispensing 429
- Nanoscale chemistry (CR) 8
- Naoyaojia (gallium complex) 249
- NAPAP 107
- Natural extracts, molecular diversity assessment 489, 490
- Natural products
- glabracins A and B 481
- glucose uptake inhibitors 481
- isolation (BR) 536, 537
- Natural resources, utility (CR) 400
- NB598 (squalene epoxidase inhibitor) 390
- NCEs *see* New chemical entities (NCEs)
- Nefazodone 475
- Neisseria gonorrhoeae*, antibiotic-resistance 495
- Neonatal brain damage, caspase inhibitors preventing 359, 360
- Neridronate, structure 70
- Networks, business 354
- Neural development, IL-6 role 203
- Neuraminidase 449
- antiviral therapy strategy 448–456
- inhibition 449, 450
- inhibitors
- early clinical studies 451
- GG167 450, 451
- Ro640796 *see* Ro640796
- Ro640802 450, 451
- as target for antiviral therapy 449–451
- Neurogen 253
- Neurokinin receptor antagonists, high-affinity 424
- Neuroleptics, in idiopathic parkinsonism 137
- Neuropeptide Y (NPY)
- control of body weight 252–254
- receptor antagonists 141, 252–254
- receptors 252
- selective antagonists 426
- Neurotoxin, binding sites for sodium channels 326
- Neurotransmitters, control of body weight 252–256
- Neurotrophic factors, in idiopathic parkinsonism 138
- Nevirapine, traceless library approach 45
- New chemical entities (NCEs)
- large pharmaceutical companies 493, 494
- required by pharmaceutical companies 343
- small biotech companies 492, 493
- New Drugs for Asthma* (CR) 395–399
- NF- $\kappa$ B
- activation/inhibition in asthma (CR) 398
- effect of oxidants/antioxidants on 120
- inhibitor 296, 425
- Nicotinic acetylcholine receptors
- ligands 89
- neuronal 240
- modulators 240, 241
- modulators characterization 241
- natural alkaloids 241
- weight control target 426
- Nitric oxide synthase
- inducible (iNOS), selective inhibitor 350
- neuronal (nNOS), inhibitors 143
- Nitrogen detectors, chemiluminescence 483, 484
- NK<sub>1</sub> receptor antagonists 191
- NMDA receptor 138
- antagonists, in idiopathic parkinsonism 137, 138
- NMR, affinity, combinatorial screening 242
- Non-nucleoside reverse transcriptase inhibitor 387
- Nonpeptide integrin antagonists 561, 562
- Nonsteroidal androgen receptor agonist 239, 240
- Novartis
- discodermolide 300
- information technology and R&D (CR) 138
- Novasomes, influenza A encapsulation (CR) 49
- Novavax, influenza A microencapsulation (CR) 49
- Novo Nordisk, Leadseeker system use 438, 439
- Nuclear hormone receptor, ligands (CR) 443
- Nuclear proteins, as drug targets 365
- Nucleic acid
- random-sequence pools 265
- generation 266, 267
- partitioning 267, 268
- see also* DNA
- Nucleic acid selection
- drug discovery tool 265–273
- implementation 273
- steps 265–268
- target validation and identification 272
- see also* Aptamers
- Nucleus, transcriptional regulation in 520, 521
- O**
- Obesity
- gene control, start-up company 99
- leptin resistance 251, 252
- neurotransmitters controlling weight 252–256
- novel molecular targets 250–256, 431 (correction)
- Obidoxime 215
- Object-orientated database management systems 548
- Object-relational databases 547–551
- management systems 548
- rapid application development (RAD) 549
- SAR spreadsheet 549, 550
- Ob/ob* mice 250, 251
- Oestrogen replacement therapy (ERT), 4-hydroxyequilenin and risk of cancer 200
- Olanzapine, in idiopathic parkinsonism 137
- Oligocarbamate libraries 563
- Oligonucleotides, antigene 45, 144 (correctors)
- Oligonucleotide synthesis
- data handling tools 38–41
- deprotection of oligomers and sorting 36

- future demands for 41, 42
- high-throughput 35–37
- large-volume sample tracking 38–41
- mass spectroscopy of products 37, 38
- purification 36
- quantitation and dispensing 36, 37
- as tool in drug discovery research 34–42
- Oligosaccharide libraries 525
- Olpadronate, structure 70
- Oncogene Science, reporter gene patent 11, 12
- Ondansetron 475
- Ontogen Corporation, object-relational databases 547–551
- Open reading frames, homology and antibiotic discovery 565
- Ophthalmology, applications of anti-TGF $\beta$  mAb (CR) 441, 442
- $\delta$ -Opioid peptide antagonists 284–294
  - conformational studies 291–293
  - design 284–294
  - strategies 286, 287
  - first generation 286
  - new lead compounds 287–291
    - diketopiperazine analogues 290–292
    - Dmt substitution of Tyr 287, 289
    - hydrophobicity enhancement 289
    - pharmacophores lacking Tic 289, 290
    - spatial modifications 289
- Opioid receptors 285
  - agonists 285, 286
  - antagonists 286
- Oral hypoglycemic agents, novel 424
- Organ chemistry, new aspects (CR) 149, 150
- Organic synthesis, 144-well synthesis chip (CR) 150
- OST577 (human mAb) (CR) 440
- Osteoporosis 69
  - alendronate for 69–77
  - bisphosphonates 73–78
  - interleukin 6 (IL-6) action 208, 209
- Out-sourcing 435, 436
  - see also Virtual companies
- Ovarian cancer cell line, novel-anti-tumor agents 522
- Oxapropylpeptide–bile acid conjugates 413, 414
- Oxazepam 472
- Oxford Glycosciences (CR) 193
- Oxford Molecular
  - Chemical Design acquisition 332
  - drug discovery research services leader 332
- Oxidosqualene cyclase inhibitors 390
- Oxycarbonyl resin 555
- P**
  - p38 $\alpha/\beta$  inhibitor (CR) 443, 444
  - p53, in phage display 374
  - P70 S6 kinase (CR) 444
  - P3622 (squalene synthase inhibitor) 389, 390
  - Packard BioScience Company, acquisition of biotechnology company 422
  - PAGE, 2D databases (CR) 194, 195
  - Paget's disease, interleukin 6 (IL-6) action 209
  - Pain, relief, Ziconotide (CR) 531
  - Pamidronate, structure 70
  - PapC, pilus biogenesis 500
  - PapD
    - bacterial pilus biogenesis 498, 499
    - inhibitors 500
  - Parallel synthesis, high-speed (HSPS) 511–515
  - Parke-Davis, investment and collaborations 200
  - Parkinsonism, idiopathic
    - antidepressants 137
    - artificial dopamine agonists 134–136
    - COMT inhibitors 131–133
    - gene therapy 138
    - local immunosuppression and transplantation 139
    - MAO inhibitors 136
    - neuroleptics 137
    - neurotrophic factors 138
    - NMDA antagonists 137, 138
    - prospects for new drugs 131–140
  - Parkinson's disease, neuronal nicotinic AChR modulators 241
  - Partnerships (business) 354
  - diagnostics companies 17, 18
  - Patenting process 52, 53
  - Patents 52
    - applications 53
    - claim drafting 54–56
    - Island Hopping* technique 490
    - market exclusivity and 52, 53
    - patentability of compounds 53–56
    - prior art searching 53–55
    - reporter genes 11, 12
    - strategies for HTS 566
  - PD132301-2 (ACAT inhibitor) 21, 23
  - PD137557 D<sub>2</sub> ligand, modification 44
  - PD138142-15 (ACAT inhibitor) 24
  - PD160170 (NPY  $\gamma_1$  receptor antagonist) 253
  - Peptide cleavage-based protease assay 460, 461
  - Peptide ligands, drug discovery 375, 376
  - Peptides
    - bile acid conjugates 413, 414
    - combinatorial, phage display see Phage display
    - directed delivery of cancer drugs 147
    - evolution 382–384
    - protein target validation 376
  - Peptidomimetics
    - design 375, 376
    - farnesyltransferase inhibition 26, 28–31
    - oncogenic signaling block 26, 28–31
  - Peptidosteroid receptor, library 417
  - Peroxisome proliferator activated receptors (PPARs)
    - ligands, library-derived 352
    - PPAR- $\delta$ , inhibitors 352
    - PPAR- $\gamma$ 
      - crystal structure and binding pocket 535, 536
      - discovery (CR) 102
      - in fat-triggered colorectal cancer 535
      - importance for pharmaceutical companies 536
      - ligand-binding domain 535, 536
      - ligand diversity 535, 536
      - troglitazone interaction 85
    - PPAR- $\gamma$  agonist, rosiglitazone 50
    - PPAR- $\gamma$  ligands 45, 535, 536
      - activation 535
  - Pfizer, new facility (CR) 199
  - pH, intracellular, indicator 142
  - Phage display 370–378
    - applications 375–377
    - peptide ligands 375, 376
    - proteins targeted 372–375
      - cell surface receptor targets 373
      - cytosolic proteins 373, 374
      - enzyme targets 375
      - streptavidin 373
      - viral protein targets 374, 375
    - screening approaches 370–372
  - Phage libraries
    - antibody libraries, for clinical diagnostics (CR) 194
    - screening 370–372
  - Pharmaceutical companies
    - activities in Japan 394
    - creativity demands and productivity 420
    - large
      - impact of virtual companies on 530

- NCE output 493, 494
  - number of NCEs required 343
  - out-sourcing trend 435, 436
  - R&D *see* R&D
  - scientists and research
    - commercialization 421
    - strategic alliances 145, 146, 353
    - trend for mergers 435
  - Pharmaceutical compounds, simplified characterization by nitrogen detection 483, 484
  - Pharmaceutical industry
    - alliances 145, 146, 353
    - challenges and opportunities 489
    - collaboration agreements 60, 67, 193
    - consolidation, expectations 488, 489
    - investment status 391, 392
    - market exclusivity and patents 52, 53
    - in Middle East 95, 96
    - new business strategies 353, 354
    - partnerships and networks 354
    - productivity 491, 492
    - spin-out company and spin-out topics 354
  - Pharmacokinetics
    - bisphosphonates 70
    - chiral drugs 248
    - troglitazone 86
  - Pharmacophores
    - Tyr-Tic 286, 287
    - in virtual screening 173, 174
  - PHARMSEARCH 58
  - Phenomics 12
  - Phenylhistin 142
  - Phenylamino-alkyl selenide compounds 51
  - Phenylpiperazines 189
  - Phosphatases
    - cytokine signaling 127, 128
    - PTP1B and TCPTP (CR) 444, 445
  - Phosphodiesterase inhibitors
    - asthma management (CR) 532, 533
    - PDE4 (CR) 532, 533
  - Phosphoramidite approach, DNA synthesis 35
  - Photoactive drugs 47, 48
  - PhotoPoint therapy 47, 48
  - Phytoalexins 235, 236
  - Phytopharm, FDA approval for Zemaphyte 60
  - Piezoelectric dispensing 429
    - applications 430
  - Piezoelectronic dispensing 148
  - PiezoTip piezoelectric dispensing technology 429, 430
  - Pilus biogenesis pathway
    - chaperone-usher assembly 497–499
    - drug target 500
  - Gram-negative bacteria
    - 496–500
    - inhibitors 500
    - PapC 500
    - PapD 498, 499
  - Plants, secondary metabolites 232–234
  - Plasmodium falciparum*
    - dihydrofolate reductase (DHFR) 538–543
    - drug discovery *see* Antimalarial drugs
    - gallium effect 103, 249 (correspondence)
  - Platelet-activating factor (PAF)
    - receptor, antagonist 424
  - Polycystic ovarian syndrome (PCOS), troglitazone treatment 87, 88
  - Polymerase chain reaction (PCR), enhancements (CR) 148, 149
  - Polymers
    - microstructuring 148
    - molecular imprinted 297
  - Positron emission tomography, chiral drugs 248
  - Postgenomic drug discovery 361, 362
  - Potassium channels 324
    - blockers, calcium-activated 190
    - blockers and activators 326
  - PPACK 107
  - PPAR $\gamma$  *see* Peroxisome proliferator activated receptors (PPARs)
  - Pramipexole
    - actions, adverse effects and dosages 132, 134, 135
    - in idiopathic parkinsonism 134, 135
  - Prazepam 472
  - Prodrug concept 235
  - Project advocate, role 358, 359
  - Project management, oligonucleotide synthesis 39, 40
  - N<sup>w</sup>-Propyl-L-arginine 143
  - PRO\_SELECT program 109
  - Prostate
    - benign hyperplasia *see* Benign prostatic hyperplasia (BPH)
    - cancer, interleukin 6 (IL-6) 207
  - Protease inhibitors, HIV, discovery (CR) 101
  - Proteasome inhibitors 295, 296
  - Protein(s)
    - analysis and identification by MS (CR) 194
    - embryonic, as drugs or drug targets 363–365
    - human, library 297, 298
    - nuclear, as drug targets 365
    - phage display 372–375
    - as targets for drugs (CR) 198
  - Protein kinases
    - inhibition/regulation 519, 534, 535
    - inhibitors 519, 520
  - Protein–protein interactions, JAK–STAT signaling pathway 126–129
  - Protein tyrosine kinases
    - drug targets 519
    - inhibitors, substrate-based 482
    - see also* Tyrosine kinases
  - Protein tyrosine phosphatase
    - substrates, combinatorial library 143
  - Proteomics (CR) 133–195
    - applications (CR) 194, 195
    - asthma drug development (CR) 398, 399
    - potential for industry (CR) 193, 194
  - Psoriasis, interleukin 6 (IL-6) 206
  - Purification methods, in combinatorial chemistry (CR) 49
  - Purine kinase inhibitor, library 94
  - Pyridoindole 543
  - 5-(2-Pyridylsulphonyl)-2-thiazolamine 239
  - Pyrimethamine, resistance 538
- Q**
- Quinazolinones (CR) 49
  - Quinidine 215
  - Quinine 234
  - Quinoline alkaloids 234
  - Quinone-based compounds 522
- R**
- Radio-frequency-encoded taxoid library 45
  - Raloxifene 211, 519
  - RANTES 517, 518
    - nonpeptidic antagonist 351
  - Rapid application development (RAD), databases 549
  - Ras farnesyltransferase 26, 27
    - inhibitors 45, 190, 191
    - design 28
    - see also* Farnesyltransferase
  - Ras protein 26, 45
    - function 26
    - oncogenic signaling 26, 27
  - R&D
    - budgets in Middle East 96
    - business flexibility needed 353, 354
    - expenditure 494
    - future predictions 487–489
    - 'innovation deficit' 491–494
    - key to company strength/future 391
    - knowledge management (CR) 197
    - management 358, 359
    - operational vs strategic management 358
    - productivity 491–494
    - providers of drug discovery elements 433
    - as science or art? 487–489
    - strategic, principles 358

- virtual *see* Virtual R&D
- virtual companies 435–437, 529–530
- Real Case Studies on Developing Effective Assays* (CR) 97–99
- Red light, penetration and applications 47
- REM linkers (CR) 48
- Renal carcinoma, interleukin 6 (IL-6) 207
- Renin, inhibitors 89
- REOS concept 170, 171
- Reporter genes, patents 11, 12
- Research and development *see* R&D
- Retinoic acid receptors (RAR), agonists 43
- Retinoid receptors 43, 90
- Retinoid X receptor, ligands 43, 90
- RGD amino acid motif 147
- Rheumatoid arthritis
  - human mAb treatment (CR) 441
  - interleukin 6 (IL-6) 206
- Rhône-Poulenc Rorer (RPR)
  - factor Xa inhibitor 227
  - high-speed parallel synthesis for lead generation 511–515
- Rilmenidine, hypertension treatment (CR) 445, 446
- Rink linkers 553, 554
- Risedronate, structure 70
- Risperidone
  - discovery (CR) 101
  - structure (CR) 101
- Ritalin 248
- Ritanserine 475
- RNA binders 563
- Ro319790 (immunomodulatory compound) 519
- Ro488071 (oxidosqualene cyclase inhibitor) 390
- Ro640796 (neuraminidase inhibitor) 452
  - efficacy in volunteers 454, 455
  - oral
    - animal models 452–454
    - clinical studies 454
- Ro640802 (neuraminidase inhibitor) 450, 451
- Robotics
  - lead optimization 506–509
  - liquid handling, nanolitre dispensing 429
- Robotic system
  - for cell culture (CR) 446
  - Core systems *see* Core system model
- Ropinorele
  - actions, adverse effects and dosages 132, 135
  - in idiopathic parkinsonism 135
- Rosiglitazone 50
  - discovery (CR) 102
- RP73163 (ACAT inhibitor) 21, 23
- RPR107393 (squalene synthase inhibitor) 389
- Rubiadin 236
- Rural Advancement Foundation International (RAFI) 401, 402
- S**
- SAGE
  - applications 157–159
    - in animal cells 158
    - diseased vs normal tissues 158, 159
    - transcriptome characterization 157, 158
  - data evaluation and method validation 155–157
  - high-throughput gene expression analysis 152–159
    - procedure 155
  - SaH57118 (ACAT inhibitor) 21
  - SaH58035 (ACAT inhibitor) 21
  - Salmonella typhimurium*, virulence and antibiotic resistance 496
  - SAM<sup>IT</sup> system 64, 65
  - Saquinavir
    - discovery (CR) 101
    - structure (CR) 102
  - SAR spreadsheet 549, 550
  - SB226552 ( $\beta_3$ -adrenoceptor agonist) 255
  - SC903 (MMP inhibitor) 423
  - SCH44342 30
  - SCH55700 (antibody to IL-5) (CR) 534
  - Schizophrenia, serotonin-2 dopamine-2 antagonists 200
  - Science, as art 419
  - Scientists
    - passion vs fear as driving force 419–422
    - pressures/demands on 420
  - Scintillation Proximity Assay (SPA) 438
    - tyrosine kinase HTRF assay comparison 336, 339, 340
  - Scorpion toxins (CR) 531, 532
  - Screening, biomolecular (CR) 7–9
  - SE205 (MMP inhibitor) 423
  - G.D. Searle & Co., antibody-based drug research collaboration 332
  - Secondary metabolites 232
    - ethnopharmacology-based approach 236
    - as leads in drug development extraction methods 236, 237
    - selection of samples 233–236
    - role as leads in drug development 232–238
  - Selectins, target in phage-display 373
  - Selenium, toxicity 51
  - Selenium compounds, antihypertensive agents 51
  - Semiconductors, gallium effect on *Plasmodium falciparum* 103, 249 (correspondence)
  - Sensor arrays 524
  - Serial analysis of gene expression *see* SAGE
  - Serine protease/proteinase inhibition, screening of virtual combinatorial library 109, 110
    - inhibitors 423
  - Serotonin
    - ligands 142
      - 5-HT<sub>2c</sub> 142
    - receptor antagonists
      - 5-HT<sub>1B</sub> receptors 189
      - 5-HT<sub>7</sub> receptor 296
    - receptors
      - 5-HT<sub>2c</sub> receptor, mice lacking 255
      - anxiolytics acting on 474, 475
      - reuptake inhibitor 142
  - Serotonin-2 dopamine-2 antagonists, market report 200
  - Sertoli cells, local immunosuppressive activity 139
  - SH2-domain-containing phosphotyrosine phosphatase I (SHP-1) 128
  - SH3 domains
    - ligands 296
    - target in phage-display 374
  - Shaman Pharmaceuticals 401
  - Sialic acid analogues, neuraminidase inhibition 449, 450
  - Signalling
    - (CR) 443–445
    - cytokines 520
    - imidazoline receptor pathway (CR) 446
    - intracellular, by kinases 519, 520
    - oncogenic cells, blocking 26–33
    - receptor tyrosine kinase pathway 26, 27
    - TNF 516
    - see also* Tyrosine kinases
  - Signalling factors, as drugs/drug targets 363–365
  - Signal transducers and activators of transcription *see* STATs
  - Signal transduction *see* Signalling
  - Silicon-containing linkers 558
  - Silicon wafers, DNA array fabrication 485
  - Single-cell systems, gene function studies 187
  - SMART anti-CD3 antibodies (CR) 440
  - SMART M195 (CR) 440
  - SMART technology (CR) 440

- Sodium channels 324, 327  
 blockers and activators 326  
 neurotoxin binding sites 326
- Software  
*InfoTech Pharma '98* (CR) 199  
 virtual screening 164
- Solid-liquid extraction (SLE) (CR) 49
- Solid-phase extraction (SPE) (CR) 49
- Solid-phase synthesis 506  
 carbohydrates, combinatorial chemistry 482, 483  
 cyclization-cleavage reactions 558, 559  
 hydroisoindole derivatives (CR) 150  
 hydroxamate 352  
 linkers for 552–560  
   *see also* Linkers  
 lipid A analogues (CR) 150  
 of small molecules 552–560
- Solution-phase combinatorial chemistry 505, 506  
 ARNIE 506  
 equipment 506, 507
- Solvent, effects, virtual screening and 175
- SPA binding assays 65
- SpectroChip® 16
- Spin-out company strategy 354
- Split hybrid systems (CR) 443
- Sponges, deep-sea 300
- Sporn, M., Award for Distinguished Achievement in Cancer Research (CR) 199
- Squalene epoxidase, inhibitors 390
- Squalene synthase, inhibitors 142, 389, 390
- SR58611A ( $\beta_3$ -adrenoceptor agonist) 255
- SR120819A (NPY  $Y_1$  receptor antagonist) 253
- SR144528 (selective CB<sub>2</sub> cannabinoid antagonist) 389
- Src-family 519
- Src-SH2-phosphotyrosine-peptide binding, fluorescence correlation spectroscopy 460
- Staff 'burn-out,' HTS laboratory 93
- Staphylococcus aureus*  
 antibiotic resistance 495, 496  
 genome sequence and ORFs 564–566  
 methicillin-resistant, drugs for 480
- Staphylococcus epidermidis*, antibiotic resistance 495, 496
- Statins 389
- STATs 122, 520  
 cytokine receptor interactions 126, 127
- cytokine signaling via 123, 124
- inactivating mutations 125, 126
- inactivation and phosphatase role 128
- structure and function 124, 125
- Stem cells  
 hematopoietic 367  
 mesenchymal 367  
 nervous system 366, 367  
 sources 366  
 as therapeutic agents 365–367
- Strain energy 175
- Strategic alliances, success rates 145, 146
- Strategic Decisions Group 358, 359
- Streptavidin, selection in phage displayed peptide libraries 373
- Streptococcus pneumoniae*, genome sequence and ORFs 564–566
- Streptomyces*, macrolides 257, 258
- Strictosidine 235
- Structure-based drug design 106, 107
- Sulphon linkers 556
- Sulphonyl linkers 556
- Supersomes™ 466–470
- Systems Integration drug Discovery Company (SIDDCO) 1, 2
- T**
- TACE (TNF-converting enzyme) inhibitors 517
- Tamoxifen, analogues 94
- Tanimoto coefficient 276, 277
- TAQ-Man approach 15, 16, 148
- Targeted combinatorial library synthesis 105–112
- Taxoids  
 new agents (CR) 149  
 radio-frequency-encoded library 45
- TBC1269, cell adhesion molecule inhibitor (CR) 533
- T-cells  
 inhibitor of AP-1 and NF- $\kappa$ B (CR) 398  
 Th2, novel receptor (T1/ST2) (CR) 397, 398
- TE802 (macrolide) 258
- Technical Advances & Applications of Proteomics in Drug Discovery, Clinical Development, Safety Testing & Diagnosis* (CR) 193–195
- Telomerase, inhibitors 523
- Tenstop 226
- Tet* operon (CR) 443
- 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (Tic) 286, 287
- pharmacophores lacking 289, 290
- 1,2,3,4-tetrahydroquinoline (THQ), retinoic acid receptor substitution 43
- Tetramic acid libraries 563
- Therapeutic antibodies (CR) 439–442  
 for acute inflammatory disorders (CR) 440  
 in kidney transplant rejection (CR) 440  
 for leukaemia (CR) 440  
 SMART anti-CD3 (CR) 440
- Therapeutic Antibodies Inc., antibody-based drug research collaboration 332
- Therapeutics, rational 4, 5
- Thienylamide 523
- Thrombin 223
- Thrombin inhibitors 224, 522, 523  
 combinatorial library 352  
 with nonbasic P1 side-chains 388  
 nonpeptidic 383, 384  
 novel 141  
 orally active 295  
 structures 107
- Thromboxane receptor, antagonists 425, 562
- Tic 286, 287  
 pharmacophores lacking 289, 290
- Tick anticoagulant peptide 225, 226
- Tiludronate, structure 70
- Tin ethyl ethipurpurin (SnET<sub>2</sub>) 47
- 7-TM receptor binding assays 461, 462
- TNF-receptor-associated death domain (TRADD) 516
- Tolcapone  
 actions, adverse effect and dosages 131–133  
 in idiopathic parkinsonism 131–133
- Topoisomerase-DNA binding, fluorescence correlation spectroscopy 459
- Topological search systems 59
- Topotecan, market share 349
- Topsentins 300
- Toxicology  
 drug metabolism and Caco-2 cell studies (CR) 8  
 troglitazone 85, 86
- Toxins, as probes of potential therapeutic targets (CR) 532
- Traceless library approach 45
- Traditional knowledge (medicines), value (CR) 400
- Training, bioinformatics 426–428
- Transcription (CR) 443–445

- regulation within nucleus 520, 521
  - Transcriptional profiling, human genome 180
  - Transcription factor, activation in asthma (CR) 398
  - Transcriptomes 157
    - SAGE characterization of 157, 158
  - Transforming growth factor- $\beta$  (TGF- $\beta$ ) 363, 364
    - human mAbs (CR) 441, 442
  - Transgenic mice, interleukin 6 (IL-6) 204
  - 7-Transmembrane receptor
    - binding assays 461, 462
  - Transplantation
    - in idiopathic parkinsonism 139
    - see also* Kidney transplant rejection
  - Triazinobenzimidazole 543
  - Trichostatin A 519
  - Trimethoprim (TMP) 539, 540
  - Trityl linkers 554
  - Troglitazone 50, 51, 79–88, 424
    - discovery 79–81
    - glucose utilization 83, 84
    - hepatic glucose production reduced 83
    - islet studies 82, 83
    - mechanism of action 84, 85
    - new applications 87, 88
    - pharmacokinetics 86
    - pharmacological profile 81, 82
    - preclinical/clinical studies 85–87
    - toxicology 85, 86
  - Tropisetron 475
  - Tuberculosis, agents from
    - M. tuberculosis* for use after heart attacks 301
  - Tubocurarine 215
  - Tumor cell lines, glabracins A and B active against 481
  - Tumor cells, overexpression of glutathione 117
  - Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), human mAb (D2E7) (CR) 441
  - Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )-converting enzyme (TACE), inhibitors 517
  - Tumor necrosis factor (TNF)
    - in inflammation, new drug targets 516, 517
    - signalling 516
    - superfamily 516
  - Tumors
    - anti-angiogenic activity of drugs 147
    - progression, MMP role 196
    - see also* Cancer
  - 2D-similarity methods, in virtual screening 165
  - Tyrosine kinases 333
    - HTRF assays 333–342, 431 (correction)
    - comparison with SPA and miniaturization 336
    - heterogeneous fluorescence format vs 336, 337
    - in-plate time-resolved fluorescence vs 340, 341
    - miniaturization 339, 340
    - optimizing reagent concentrations 337, 338
    - principles 334, 335
    - procedures 336, 337
  - inhibitors
    - identification by HTRF 338, 339
    - screening methods 333, 334
  - signal transduction pathway 26, 27
  - structure (CR) 534
  - see also* Protein tyrosine kinases
  - Tyrosine phosphatases
    - cytokine signaling 127, 128
    - STATs inactivation 128
  - Tyrosine phosphorylation, cytokine signaling 127, 128
  - Tyr-Tic 286, 287
- U**
- Ugi reaction 383, 384
  - Ultra-high-throughput screening (UHTS) 299, 349
    - imaging systems 438, 439
    - levels achieved 192
- V**
- Validation
    - microtiter plate assay for CYP2D6 inhibition 466–470
    - of protein targets, peptides for 376
  - Vallesiachotamine 235
  - 'Vascular addresses' 147
  - Vascular endothelial growth factor (VEGF) 363
  - Vector technology, for gene therapy, in Japan 393
  - Venlafaxine, in idiopathic parkinsonism 137
  - Venoms, drugs from (CR) 531, 532
  - Verapamil 215
  - Vertebral fractures 76, 77
  - Very low density lipoproteins (VLDL) 19
  - Viral proteins, target in phage display 374, 375
  - Virtual companies 529, 530
    - interview with founder (Arachnova) 435–437
    - specific companies and strategies 529
  - Virtual library
    - 3D 171, 172
    - 3D vs 2D descriptors 281, 282
    - design 274–283
    - reasons for 274, 275
    - directed 274
    - issues and controversies 281, 282
    - screening 274
      - design approaches 275
    - selection methods 275–281
      - grid-based 278, 279
      - other methods 281
      - similarity-based 276–278
      - structure-based 279, 280
  - Virtual R&D 435–437
    - advantages 437
  - Virtual screening 160–178
    - 2D-similarity methods 165
    - applying information to 164
    - combinatorial library 107, 108
    - current practices 164–168
    - detailed analyses 168–172
    - docking and scoring 172–176
    - factors affecting search strategy 163, 164
    - improvement prospects 168
    - limiting search space 162–164
    - software 164
    - traditional screening vs 161, 162
  - Virulence, bacteria 496
  - Visible Genetics Inc. 15
    - HIV genotyping kits collaboration 60
  - Vitreoretinopathy, proliferative, applications of anti-TGF $\beta$  mAb (CR) 441
  - Voltage-gated ion channels 323
    - drug discovery using HTS 323–332
    - families 324
    - future technologies for drug discovery 331
  - HTS
    - automation/miniaturization 331
    - HTS program 330
    - HTS techniques 323, 325–330
      - cell-based fluorescence 326–329
      - cell viability 329, 330
      - electrophysiology 330
      - radioligand binding 325, 326
    - libraries for 330, 331
- W**
- W84 214, 215, 218
  - Wang linkers 553
  - WDuo3 215
  - Weight control
    - molecular targets 426
    - by neurotransmitters 252–256
  - Wet-chip devices 405–408
    - 'activation' 405
    - arbitrary synthesis design 406, 407
    - branched screening design 407, 408

branched synthesis design 408  
 combinatorial synthesis design 408  
 for drug discovery 406–408  
 linear synthesis and screening design 407  
 Workstation approach, oligonucleotide synthesis 34–42  
 World Wide Web  
   design and scientific communities 243  
   influenza virus database 442  
   science 243, 244  
   *see also* Internet  
 WR99210 (antimalarial) 546

## X

Xenova, investment and collaborations 200  
 X-ray crystallography  
   Erk2 and diphospho-Erk2 (CR) 443, 444  
   p38 $\alpha$ / $\beta$  inhibitor (CR) 443, 444

## Y

Yagin 226  
 Yamanouch Pharmaceutical, factor Xa inhibitor 227  
 Yeast gene expression, SAGE characterization of 157  
 YH529 (bisphosphonate), structure 70

## Z

Zacopride 475  
 Zanamivir (GG167) 450, 451  
 Zaragozic acid A analog 32  
 ZD1839 (immunomodulatory compounds) 519  
 Zebrafish, brain development model 13  
 Zemaphyte, FDA approval 60  
 Zenapax® (humanized antibodies) (CR) 439  
 Zeneca  
   bioinformatics and IT systems (CR) 197  
   factor Xa inhibitor 227  
 Ziconotide (CR) 531  
 Zinc fingers, artificial (CR) 443  
 Zoledronate, structure 70